Epizyme, Inc. (EPZM) Insider Peter Tai-Ching Ho Sells 15,000 Shares
Epizyme, Inc. (NASDAQ:EPZM) insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $15.68, for a total transaction of $235,200.00. Following the transaction, the insider now directly owns 22,228 shares in the company, valued at $348,535.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Peter Tai-Ching Ho also recently made the following trade(s):
- On Monday, July 24th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00.
- On Monday, June 26th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $14.87, for a total transaction of $223,050.00.
Epizyme, Inc. (EPZM) opened at 16.50 on Tuesday. The firm’s market cap is $964.69 million. The company has a 50 day moving average of $13.73 and a 200-day moving average of $14.67. Epizyme, Inc. has a one year low of $7.02 and a one year high of $18.50.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10 million during the quarter, compared to analyst estimates of $3.95 million. During the same period in the previous year, the company earned ($0.49) EPS. The company’s revenue for the quarter was up 2027.7% on a year-over-year basis. On average, equities research analysts predict that Epizyme, Inc. will post ($2.39) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Epizyme, Inc. (EPZM) Insider Peter Tai-Ching Ho Sells 15,000 Shares” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/29/epizyme-inc-epzm-insider-peter-tai-ching-ho-sells-15000-shares.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc raised its position in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. acquired a new position in shares of Epizyme during the first quarter worth approximately $175,000. BB&T Securities LLC acquired a new position in shares of Epizyme during the second quarter worth approximately $181,000. Trexquant Investment LP acquired a new position in shares of Epizyme during the second quarter worth approximately $184,000. Finally, SG Americas Securities LLC raised its position in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the period. Institutional investors own 83.74% of the company’s stock.
EPZM has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, May 16th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Epizyme and gave the company a “buy” rating in a research note on Monday, June 5th. Cann reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Wednesday, June 21st. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $23.38.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.